Today, OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of ...

Acute Myeloid Leukemia is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally.​ -With relapse rates as high as 50%, routine measurable residual disease (MRD) ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

FOSTER CITY, Calif., May 30, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual ...

Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out Clinical trials frequently include multiple end points that mature at different times. The initial report, ...

MRD detection is the future — allowing us to monitor patients in real-time. The data is strong and we're excited that our approach can now be incorporated into future studies." Dr. Roy Herbst, study's ...

Liquid biopsies are rapidly becoming an essential tool for monitoring minimal residual disease (MRD) in cancer treatment. Analyzing cell-free DNA (cfDNA) allows for the detection of tumor-specific ...

SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ --Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced ...